CereGate
Key Facts
| Invested since | 2019 |
| Based in | Hamburg |
About the company
CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced treatment of various neurological and psychiatric disorders. The CereGate platform is able to transmit information into the brain („Mind-Writing“), by utilizing state of the art neuromodulation technology. While focusing first on improving gait symptoms for Parkinson patients, CereGate aims to become a key enabling tech¬nology in the field of rehabilitation and (neuro)prosthetics.
Do you want to
know more about this company?
CereGate in the news
zum Artikel
CereGate, the preeminent Computer-Brain-Interface Software Platform, advances in clinical development and secures financing from leading deep tech and mental health investors 468 Capital and re.Mind Capital
zum Artikel
CereGate GmbH receives financing from High-Tech Gründerfonds to accelerate development of a new software platform for neuromodulation therapy
More startups from Life Sciences
EvlaBio is a life science company focused on developing first-in-class therapeutics for cardiovascular and cardiorenal diseases. Its lead program targets the FGFR4/FGF23 signaling axis, a critical driver of cardiac remodeling …
to EvlaBio
Exit
Vector-based technologies for cell and gene therapy applications and vaccines
to SIRION Biotech
HBOX Therapies has developed a technology that facilitates lung-protective treatment of respiratory patients, the patented platform technology HBOX (Hyperbaric Blood Oxygenation). The management team of HBOX Therapies consists of the …
to HBOX Therapies
Exit
Cunesoft provides pioneering online regulatory software for the life sciences and other regulated industries. The SaaS (Software as a Service) based solutions are delivered fully functional to customers and fulfill …
to Cunesoft
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA …
to Pantherna Therapeutics
Exit
The core competency of AQ Implants GmbH is the endoprosthetic reconstruction of severe and complex defects and anomalies. With the development of innovative implant systems AQ Implants GmbH provides surgeons …
to AQ Implants
Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible …
to cutanos
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
to Synendos Therapeuthics
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
to Draupnir Bio
Smarterials Technology GmbH is a young MedTech company with high competence in the fields of inorganic chemistry, surface functionalization and process technology. The company was founded by two material scientists …
to Smarterials Technology
C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential …
to C-mo
Development of enhanced antibody-drug conjugates for improved cancer treatment
to Tubulis